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Multiple Sclerosis (MS) is an autoimmune disease where the patient’s own 
immune system attacks the myelin cover of his nerves, causing communication problems 
between the brain and the rest of the body. Currently there is no cure for MS, however 
treatments can slow down the progression of MS by reducing the frequency and severity 
of attacks and the development of new brain lesions. Dr. Babensee’s lab aims to relive 
effects and symptoms of MS by utilizing interleukin-10 (IL-10), an anti-inflammatory 
cytokine to induce immunosuppressive tolerogenic dendritic cells (DCs). The purpose of 
this study is to design a delivery system of IL-10 with high loading efficiency and allows 
for adjustable release profile. Ovalbumin (OVA), a main protein found in egg white, was 
chosen as a less costly model for IL-10 for this project due to its similar physical and 
chemical properties to IL-10. Early stages of this study focused on creating an OVA 
incorporated 4-arm polyethylene glycol maleimide (PEG-4MAL) by chemically attaching 
OVA to the molecule’s maleimide group. A variety of molar ratios of PEG-4MAL and 
OVA were examined to determine the ratio that provides the highest loading efficiency. 
Results have shown that a 3:1 molar ratio of PEG-4MAL and OVA offers the highest 
loading efficiency. Later stages of the study focused on designing a IL-10 attached PEG-
4MAL microgel, which allows for more control over the release profile of IL-10. The 
microgels are created using a microfluidic device with flow-focusing geometry in the 
Garcia Lab at Georgia Tech.  
The anticipated outcome of this project is to create a IL-10 incorporated 
microgel system that allows for less invasion, more targeted release of IL-10 and more 
 x 
control over the release profile of IL-10 to provide an immunosuppressive environment 






 Multiple sclerosis (MS) is the most widespread disabling neurological condition of 
young adults around the world.1 The Multiple Sclerosis Foundation estimates that more 
than 400,000 people in the United States and about 2.5 million people around the world 
have MS. 1 About 200 new cases are diagnosed each week in the United States. There is 
no cure for MS. Medication are designed to lessen frequency of relapses and slows the 
progression of the disease.1 MS is a disease in which the myelin covers of nerve cells in 
the brain and spinal cord are attacked and damaged by the patient’s immune system.2 
This damage disrupts the ability of parts of the nervous system to communicate, resulting 
in a range of symptoms including double vision, blindness in one eye, muscle weakness, 
or trouble with coordination.2 Previous research has suggested that the phenotype of 
dendritic cells (DCs), a type of immune cell, is a significant contributor to the 
pathogenicity of MS.3 Research has also shown that by inducing tolerogenicity in DCs, 
these cells can be used as a treatment for MS. Tolerogenic cells (tol-DCs ) are 
traditionally created by the body as an adaptation mechanism for implants and new drugs, 
and many therapies have looked at increasing the presence of tol-DCs and decreasing the 
presence of mature DCs. 4Tolerogenicity in DCs can be induced by the presence of the 
cytokine interleukin-10 (IL-10), which has been considered to have a potential 
therapeutic role in autoimmune diseases. 5Although IL-10 has been proven to induce 
tolerogenicity, few research has been done on creating an effective delivery system for 
IL-10.  
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 Specifically, the project outlined is focused on designing a delivery system of 
IL-10 that allows for minimum invasiveness and control over the release profile. At 
early stages of this project, a 50μL 4-arm polyethylene glycol-maleimide (PEG-
4MAL) hydrogel matrix that incorporated chemically attached IL-10 to the molecule’s 
maleimide group was developed. Although a high attachment ratio was achieved 
through experiments, this PEG-4MAL matrix was largely invasive and allowed for little 
control over the release profile. Later stages of the project focused on designing a PEG-
4MAL microgels that would be diffusively-loaded with IL-10 and incorporated into a 50 
μL PEG-4MAL hydrogel matrix. These microgels were based on those previously 
created by the Garcia Lab at Georgia Tech6,7. Theoretically, by confining IL-10 
concentrations to these microgels, they will act as diffusional beads that release IL-10 
into the matrix, giving the system greater control of IL-10 release into the bulk hydrogel 
matrix and subsequently into the subject. This IL-10 delivery system is developed for 
the purpose of injecting the incorporated IL-10 into mice models with induced 
experimental autoimmune encephalomyelitis (EAE), which mimics MS. The goal is to 
see an increase in the lifespan of a mouse with induced EAE and lessen disease severity 
through neurological deficits, after the injection of the delivery system of IL-10. This 
would model the large-scale disease of MS in a patient and the ability to extend their life 








LITERATURE REVIEW   
Dendritic Cells in Multiple Sclerosis   
Multiple Sclerosis is a chronic autoimmune disease predominantly mediated by T-
cells.4 It has been proposed that autoreactive myelin-specific CD4+ (Th1 and Th17) and 
CD8+ T cells that have primed in the periphery migrate to the CNS where they cause 
demyelination and axonal loss.4 MS is believed to be a result of an imbalanced immune 
tolerance network. Therefore an ideal therapy for MS would be to re-establish antigen-
specific peripheral tolerance. Tolerogenic cells (tol-DCs), a group of antigen presenting 
cells, are key players in balancing immunity versus tolerance. Shown in Figure1, the 
generation of tol-DCs from relapsing-remitting multiple sclerosis (RR-MS) patients ex 
vivo using a pro-inflammatory cytokine cocktail in the presence of vitamin D3 has been 
described as a strategy by Raich-Regue et al., These tol-DCs induce hyporesponsiveness 
in myelin-reactive CD4+ T cells by inducing anergy, apoptosis, phenotypic skewing, 
and/or Treg cells.4 Immature DCs (iDCs) are located in the periphery tissues where they 
constantly encounter antigens.3 While pro-inflammatory cytokines induce maturation into 
immunogenic DCs, anti-inflammatory cytokines inducing IL-10 induce DCs with a more 
tolerogenic phenotype.5 Therefore, targeting DCs for MS aim to enhance their 
tolerogenic features.  
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Figure1. Use of tolDCs to restablish the balance of immunity and tolerance in MS.4 
 
IL-10 Induces Tolerogenicity   
Previous research has shown that interaction with IL-10 treated DCs rendered 
antigen-specific T cells unresponsive and their injection reduced the severity of 
experimental autoimmune disease.5 In one study done by Wright et al., experimental data 
suggest that IL-10 acts not by inhibiting maturation but instead by controlling the kinetics 
and the quality of DC activation.4 In another study done by Boks et al., tol-DCs were 
generated with vitamin D3, IL-10, dexamethasone, TGFβ or rapamycin and among 
them, IL-10 DC showed most powerful tolerogenic characteristics with low T cell 
activation.5 Moreover, in a functional suppression assay only IL-10 DC induced Treg that 
strongly suppressed T cell activity5. Thus, IL-10 DCs show functional characteristics that 




   Hydrogel microparticles (microgels) have been used in broad biomedical applications 
including cell encapsulation and transplantation, wound healing, and protein and drug 
delivery.9 Traditional bulk gels are usually injected through invasive surgery and can 
induce complications such as infection and scarring. In comparison, microgels can be 
delivered via small diameter needles and therefore are less invasive. Furthermore, if 
properly sized, microgels are able to conform to the geometry of the site of interest, 
which promotes uniform distribution of the drug delivered.9 In a study done by Foster et 
al., microgels were developed via microfluidics-based polymerization. Vascular 
endothelial growth factor (VEGF) was covalently tethered within the microgel network 
and the release rate was adjusted by changing the ratio of degradable and non-degradable 
crosslinkers.6 Results showed that controlled release of VEGF from the microgels 
increased vascularization.6 In another study done by Headen et al., four molecules of 
different molecular weight, glucose, insulin, immunoglobulin G (IgG) and bovine serum 
albumin (BSA) were encapsulated within microgels generated from a 20kDa PEG-4MAL 
macromer, and the rate of their release into buffer was measured.7 Results show nearly 
100% release for the smaller molecules glucose and insulin. The study also demonstrate 
that the network structure can be tuned for control over release profile. Specifically, IgG 
was encapsulated in microgels made with PEG macromers of 10kDa and 20kDa. Results 




MATERIALS AND METHODS  
Ovalbumin PEGylation  
          Due to the high cost of IL-10, ovalbumin (OVA) was used as a less costly 
model for IL-10 in this project. Ovalbumin was dissolved in 2mM EDTA solution in PBS 
with a concentration of 2mg/ml. Traut’s Reagent was then added to the OVA solution to 
make a 20-fold molar excess. The mixed solution will be well mixed by sitting on the 
shaker plate for 1 hour. PEG solutions of various concentrations were made and mixed 
with OVA solution to make 4:1, 3:1, 2:1 and 1:1 molar ratio of PEG and OVA. The 
mixed solution is incubated at 37°C for 30 minutes.  
 
Ellman’s test 
         Ellman’s Reagent is used to determine the concentration of any macromolecule 
in a solution that is thiolated, or contains an H-S group attached. Reaction buffer was first 
made by dissolving Na3PO4 in 1mM EDTA solution with pH of 8 to make a 0.1M 
solution. Next Ellman’s reagent solution is made by dissolving 4mg Ellman’s reagent in 
1mL reaction buffer. And working buffer was mode by mixing 75μL Ellman’s reagent 
solution in 3.75mL reaction buffer. Serial dilutions for cysteine standard curve was made. 
12.5μL of samples, cysteine standards, thiolated OVA and non-thiolated OVA, 
respectively was pipetted into triplicates in a 96-well plate, 128μL of the working 
solution was added to each of the wells, making a total of 140.5 μL in each well. The 
plate then sat in artificial light for 15 minutes and iControl will be used to read the 
absorbances at 412nm.  
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Gel Electrophoresis  
     Thirty microliters of each sample and 8 μL of protein standard was mixed with 
loading buffer, respectively. Each mixture was incubated for 5 minutes at 60°C. The 
bathed samples were then loaded into separate wells of the polyacrylamide gel, which 
was placed in the gel tank filled with running buffer up to the upper edge of the wells. 
The gel tank was connected to a power of 165V, 130mA. The polyacrylamide gel was 
then run for 35 minutes. After 35 minutes, the polyacrylamide gel was dyed with 
Cassesin blue for 40 minutes. Finally the gel will be washed repeatedly with water until it 




Dendritic Cell Culture  
Immature murine DCs were cultured in order to test the ability of microparticles 
loaded with IL-10 and soluble IL-10 to induce tolerogenicity.   
After counting the cells and the final wash, the cells were resuspended in DC 
media at a concentration of 1x106 cells/mL. The cells were plated in well plates at 3 mL 
per well. Sixty nanograms of GM-CSF and IL-4 were added to each well. The plate was 
then placed in the incubator. The cells were fed every 2 days and treated on day 6. On 
Day 2 the plates were removed from the incubator and swirled gently to remove any 
slightly adherent cells from the walls. Half of the solution was taken from each well (~1.5 
mL) and placed in a conical. The conical was then spun in the centrifuge and the fluid 
aspirated. The cells were resuspended in DC media and 1.5 mL is put back in each well.  
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Sixty nanograms of GM-CSF and IL-4 was added to each well and the plates are placed 
back in the incubator. This same process was repeated on Day 4. 
 
Microparticle Loading  
After the particles were received, the number of particles was counted using a 
hemocytometer so that later the volume of the desired amount of particles can be 
calculated. Although 4050 of both air-dried and freeze-dried particles was used during 
the experiment, 5000 of both air-dried and freeze-dried particles was removed from the 
stock in order to have excess. Since currently, the hydrogel implant used 2.5ng of IL-10 
per 50,000 cells to induce tolerogenicity, this ratio of IL-10 to cells should be replicated 
in this experiment. Additionally, the effect of particle concentrations per well was 
explored. Combining these factors, the middle concentration (450 particles per well) 
contained the 2.5ng per 50,000 cell ratio that had been used in the hydrogel implant. But 
to keep diffusion kinetics the same, all particles was loaded with the same amount of IL-
10. So all particles was loaded at 0.00556 ng IL-10 per particle, or 27.78ng IL-10 per 
5000 particles. In the wells with 600 particles, this was the equivalent of 3.33ng of IL-10 
per well. In the wells with 300 particles, this was the equivalent of 1.67ng of IL-10 per 
well. Control wells with similar amounts of dissolved IL-10 and no particles was used.  
 
A. Freeze-dried microparticles  
Once the particle concentration was determined using a hemocytometer, 5000 
particles will be removed from the particle stock by pipetting and placed in the centrifuge 
tube. The stock should be thoroughly mixed so to ensure even distribution of particles in 
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solution when removing particles from stock. The particles should then be freeze-dried. 
After these particles were freeze-dried, particles will be loaded by adding 10 μL of media 
with 27.78 ng of dissolved IL-10. Then media in 5μL increments was added to the 
microparticles until they are fully saturated. By only just saturating the particles, the IL-
10 was more likely to diffuse completely into the particle. The IL-10 was allowed to 




B. Air-dried microparticles  
Five thousand particles were removed from the particle stock and placed in the 
centrifuge tube in the same way as for the freeze-dried microparticles procedure. The 
particles should then be air dried. After these particles were air-dried, particles were 
loaded by adding 10 μL of media with 27.78 ng of dissolved IL-10. Then media in 5μL 
increments was added to the microparticles until they are fully saturated. By only just 
saturating the particles, the IL-10 was more likely to diffuse completely into the particle. 




Fifty thousand immature dendritic cells in 100uL media were plated per well in 
triplicates in a 96 well plate. Then a Corning tissue-cultured transwell with 0.4μm pore 
size PET membrane was placed on top of the 96 well plate. This transwell separated the 
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particles from the cells but allow IL-10 to diffuse through the membrane. 0.4μm PET was 
chosen for the transwell because the small pore size does not allow microparticles to 
diffuse through the membrane into the cells, but allows IL-10 to cross and induce 
tolerogenicity in the cells. Additionally, if needed, PET is transparent so fluorescence 
spectroscopy can be done with the transwells in the plate. A graphic of how these wells 
was setup with the transwell can be seen in Figure 2.  
To each transwell, either 50μL of freeze-dried particles or 50 μL of air-dried 
particles was added in triplicate. Each row of the 96 well plate had different amount of 
particles (600 particles/well or 12 particles/μL, 450 particles/well or 9 particles/μL and 
300 particles or 6 particles/μL). This setup can be seen in Figure 2. To accomplish the 
different numbers of particles per well, freeze-dried particles stock was first diluted with 
media so that the particles have a concentration of 12 particles/μL. 50 μL of this stock 
was then be added to each of the appropriate 3 wells. The stock was then diluted to 9 
particles/μL, and 50 μL of this stock will be added to the appropriate 3 wells. The stock 
was diluted once more to 6 particles/μL, from which 50 μL was placed into the 
appropriate wells. This process of plating these dilutions was repeated with the air dried 
particles stock.  
A panel of positive controls was also run. The positive controls did not have 
particles, but was given a treatment of 150μL of IL-10 at varying concentrations in 
culture media. The volume of media will be the same as the volume of particles given to 
the respective wells with particles. The concentrations of IL-10 given in the positive 
control can be seen in Figure 2 and mirror the amount of IL-10 delivered by particles in 
the air dried and freeze-dried particle wells. Several negative controls were also run in 
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triplicate, which had cells but not IL-10. The first negative control had iDCs. The second 
treatment control was tolerogenic dendritic cells plated. The third control had mature 
dendritic cells plated, induced with treatment with different concentrations of IL-10 
shown in Figure 2.  
 After 48 hours of incubation at 37°C and 5% CO2, the tolerogenicity of the 
dendritic cells was tested via the fluorescent spectroscopy protocol below.  
 
 Number of 




 Air dried particles  (+) control 
No particles, IL-10 
(ng) 
600         3.33 3.33 3.33 
450         2.5 2.5 2.5 
300         1.67 1.67 1.67 
            
 (-)Control  
iDC + media 
(triplicate) 
 (-) control 
 tDC + media 
(triplicate) 
 (-)control 
mDC + media 
(triplicate) 




Figure 3. Graphic of well with transwell, particles, and cells 
 
Fluorescence Spectroscopy  
After plating the cell and running the reaction, fluorescence test is used to test 
tolerogenecity of the cells. For this, the transparent transwell was carefully removed 
without spilling media. The contents of each well were then transferred via pipetting to a 
black 96-filter plate that is stacked on top of a new 96-well plate. The setup of the 
original 96-well plate should be maintained when the contents are transferred. Contents 
were then centrifuged at 300 RCF for 4 minutes to filter out media. Next, the filter plate 
was stacked on a new 96 well plate for fixing cells. One hundred microliters of 4% 
formaldehyde solution was added to the retained cells, and cells were allowed to fix for 
40 minutes at room temperature while being shaken at 600 RPM. Then formaldehyde 
solution was removed via centrifugation at 400 RCF for 4 minutes. Then the filter plate 
was stacked onto a new 96 well plate. Antibodies were added for immunostaining. 
Background fluorescence subtraction was measured. After 30 minutes of staining, cells 
were washed with a wash solution of 0.1% BSA and 2mM EDTA in PBS, pH 7.20. The 
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excitation/emission wavelengths for each fluorophore are 535/590 for R-phycoerythrin 
(PE), 485/535 for fluorescein isothiocyanate (FITC) , and 650/668 for Allophycocyanin 
(APC). A Tecan Infinite F500 microplate reader was set up at appropriate wavelengths 
for excitation and emission to measure the geometric mean fluorescent intensities 
(gMFIs, example shown in Figure 4). 
 
Figure 4. Geometric mean fluorescent intensities. Different colors indicate different 
emission and excitation as indicated above the figure. 
 
At last, the ratio of respective gMFIs (CD86/DC-SIGN), a cell number 
independent metric named “inflammatory maturation factor” (IMF), and PiRB/CD86 (a 
cell number independent metric named “tolerogenic maturation factor” (TMF)) were 








Ellman’s test  
      Concentrations of free thiol groups in 7 samples were tested using Ellman’s assay. 
4 of them was made by mixing different molar ratios (4:1, 3:1, 2:1 and 1:1) of PEG 
molecules and OVA molecules. The other three are thiolated OVA without PEG groups, 
unthiolated OVA and PEG molecules. As shown in Figure5, among the 4 samples made 
by mixing different molar ratios of PEG and OVA, the sample made by mixing a 3:1 
molar ratio of PEG and OVA has the least amount of free thiol groups, which indicates 
that a 3:1 molar ratio of PEG and OVA produces the highest attachment efficiency.  
 
 
Figure5. Concentrations of free thiol groups in samples made by mixing PEG 
molecules and OVA molecules of different ratios (1:1, 2:1, 3:1, 4:1), thiolated OVA, 



























Gel electrophoresis  
         Protein standards, 1:1 PEG-OVA, 2:1 PEG-OVA, 3:1 PEG-OV, 4:1 PEG-
OVA and thiolated OVA were loaded from left to right into the wells of polyacrylamide 
gel. As can be seen from Figure6, each band corresponds to each sample and the 
molecular weight marker is labeled on the left. The result shows a higher degree of 
attachment in the 3:1 PEG-OVA and 4:1 PEG-OVA samples, indicated by a darker blue 
color on the top of those 2 bands.  
 
Figure6. Polyacrylamide gel. Columns correspond to: molecular weight standards; 
1:1 PEG-OVA; 2:1 PEG-OVA; 3:1 PEG-OVA; 4:1 PEG-OVA; thiolated OVA, 
(from left to right). Representative of polyacrylamide gel electrophoresis result. 
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Expected Results of microgel protocol  
Due to the time and material constraint, we were not able to perform experiments 
following protocols above. However, we expect the following results. IL-10 should 
completely diffuse into the microparticles in the time allotted. These particles should 
have a more sustained IL-10 release rate as compared to the release of soluble IL-10 
particles directly in solution. This should result in cells incubated with particles having 
similar tolerogenicity profiles as cells incubated with soluble IL-10. Consequently, 
fluorescent test should indicate matching excitation peak in cells incubated with particles 
and without particles. However, there may be differences in tolerogenicity between 
particles that have been freeze-dried versus air dried. With the outcome of controlled 
experiment of particle loading, the better drying method between freeze drying and air 
















     From the experiments conducted and stated in the results, a 3:1 molar ratio of PEG 
and OVA produces the highest degree of chemical attachment. Shown by the Ellman’s 
test results, the degree of chemical attachment increases as the molar ratio of PEG and 
OVA increases from 1:1 to 3:1 and there is a sharp drop at 4:1 molar ratio. Theoretically 
at most 4 PEG molecules can be chemically attached to one OVA molecule since there 
are four binding sites for PEG molecules on one OVA molecule. This sharp drop in 
degree of attachment is most likely due to steric hindrance. The gel electrophoresis result 
also confirms this conclusion. However, the results for Ellman’s test and gel 
electrophoresis stated are drawn from less than 3 trails of experiments so they can be not 
100% reliable. Furthermore, due to time constraint, we were not able to conduct 
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